Download PDF
Semin Respir Crit Care Med 2004; 25(3): 345-352
DOI: 10.1055/s-2004-829506
Copyright © 2004 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA.

Vaccination against Tuberculosis: Current Status and Future Promise

Stefan H. E. Kaufmann1 , Hans-Willi Mittrücker1
  • 1Max Planck Institute for Infection Biology, Department of Immunology, Berlin, Germany
Further Information

Publication History

Publication Date:
29 June 2004 (online)

    Permissions and Reprints

Tuberculosis remains a major health threat. The currently available vaccine, bacille Calmette-Guérin (BCG), provides insufficient protection, and multi-drug-resistant strains are on the rise. A novel vaccine with higher efficacy is needed for satisfactory control of the disease. Currently, several novel vaccine candidates are being tested in preclinical models with promising outcome, but none with overwhelming success. The final decision as to whether an efficacious vaccine can be designed will have to await the outcome of a clinical trial comprising the most promising candidates identified by experimental animal studies.

KEYWORDS

Tuberculosis - vaccination - BCG - T lymphocyte - granuloma - correlate of protection - attenuation

REFERENCES

  • 1 Collins H L, Kaufmann S HE. Prospects for better tubercolosis vaccines.  Lancet Infect Dis. 2001;  1 21-28
    PubMedGoogle Scholar
  • 2 Kaufmann S HE. How can immunology contribute to the control of tubercolosis?.  Nat Rev Immunol. 2001;  1 20-30
    CrossrefPubMedGoogle Scholar
  • 3 Fine P EM. The BCG story: lessons from the past and implications for the future.  Rev Infect Dis. 1989;  11 S353-S359
    PubMedGoogle Scholar
  • 4 Kaufmann S HE. Is the development of a new tuberculosis vaccine possible?.  Nat Med. 2000;  6 955-960
    PubMedGoogle Scholar
  • 5 Casadevall A, Pirofski L A. Exploiting the redundancy in the immune system: vaccines can mediate protection by eliciting “unnatural” immunity.  J Exp Med. 2003;  197 1401-1404
    CrossrefPubMedGoogle Scholar
  • 6 Van Rie A, Warren R, Richardson M et al.. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment.  N Engl J Med. 1999;  341 1174-1179
    CrossrefPubMedGoogle Scholar
  • 7 Casanova J-L, Abel L. Genetic dissection of immunity to mycobacteria: the human model.  Annu Rev Immunol. 2002;  20 581-620
    CrossrefPubMedGoogle Scholar
  • 8 Clements C J. Vaccination: the current status of BCG. In: Kaufmann SHE, Hahn H Mycobacteria and TB. Basel; Karger 2003: 46-66
    Google Scholar
  • 9 Reiter H. Die Säuglingstuberkulose in Lübeck. Berlin; Julius Springer 1935
    Google Scholar
  • 10 Colditz G A, Brewer T F, Berkey C S et al.. Efficacy of BCG vaccine in the prevention of tuberculosis: meta-analysis of the published literature.  JAMA. 1994;  271 698-702
    CrossrefPubMedGoogle Scholar
  • 11 Stanford J L, Shield M J, Rook G AW. How environmental mycobacteria may pre-determine the protective efficacy of BCG.  Tubercle. 1981;  62 55-62
    CrossrefPubMedGoogle Scholar
  • 12 Palmer C E, Long M W. Effects of infection with atypical mycobacteria on BCG vaccination and tuberculosis.  Am Rev Resp Dis. 1966;  94 553
    PubMedGoogle Scholar
  • 13 Brandt L, Feino Cunha J, Weinreich Olsen A et al.. Failure of the Mycobacterium bovis BCG vaccine: some species of environmental mycobacteria block multiplication of BCG and induction of protective immunity to tuberculosis.  Infect Immun. 2002;  70 672-678
    CrossrefPubMedGoogle Scholar
  • 14 Schaible U E, Collins H L, Kaufmann S HE. Confrontation between intracellular bacteria and the immune system.  Adv Immunol. 1999;  71 267-377
    PubMedGoogle Scholar
  • 15 Janeway Jr C A, Medzhitov R. Innate immune recognition.  Annu Rev Immunol. 2002;  20 197-216
    CrossrefPubMedGoogle Scholar
  • 16 Brightbill H D, Libraty D H, Krutzik S R et al.. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors.  Science. 1999;  285 732-736
    CrossrefPubMedGoogle Scholar
  • 17 Kaufmann S HE. Protection against tuberculosis: cytokines, T cells, and macrophages.  Ann Rheum Dis. 2002;  61 54-58
    PubMedGoogle Scholar
  • 18 Geijtenbeek T BH, van Vliet S J, Koppel E A et al.. Mycobacteria target DC-SIGN to suppress dendritic cell function.  J Exp Med. 2002;  197 7-17
    PubMedGoogle Scholar
  • 19 Tailleux L, Schwartz O, Herrmann J L et al.. DC-SIGN is the major Mycobacterium tuberculosis receptor on human dendritic cells.  J Exp Med. 2002;  197 121-127
    PubMedGoogle Scholar
  • 20 Kaufmann S HE, Schaible U E. A dangerous liaison between the two major killers: M. tuberculosis and HIV target in dendritic cells through DC-SIGN.  J Exp Med. 2003;  197 1-5
    CrossrefPubMedGoogle Scholar
  • 21 Raupach B, Kaufmann S HE. Immune response to intracellular bacteria.  Curr Opin Immunol. 2001;  13 417-428
    CrossrefPubMedGoogle Scholar
  • 22 Schaible U E, Winau F, Sieling P A et al.. Apoptosis facilitates antigen presentation to T lymphocytes through MHC-I and CD1 in tuberculosis.  Nat Med. 2003;  9 1039-1046
    PubMedGoogle Scholar
  • 23 Pancholi P, Mirza A, Bhardwaj N, Steinman R M. Sequestration from immune CD4+ T-cells of mycobacteria growing in human macrophages.  Science. 1993;  260 984-986
    PubMedGoogle Scholar
  • 24 Kaufmann S HE. Gamma/delta and other unconventional T lymphocytes: what do they see and what do they do?.  Proc Natl Acad Sci USA. 1996;  93 2272-2279
    CrossrefPubMedGoogle Scholar
  • 25 Schaible U E, Kaufmann S HE. CD1 and CD1-restricted T cells in infections with intracellular bacteria.  Trends Microbiol. 2000;  8 419-425
    CrossrefPubMedGoogle Scholar
  • 26 Shen Y, Zhou D J, Qiu L Y et al.. Adaptive immune response of Vγ2 Vδ2 T cells during mycobacterial infections.  Science. 2002;  295 2255-2258
    CrossrefPubMedGoogle Scholar
  • 27 Brandt L, Elhay M, Rosenkrands I, Lindblad E B, Andersen P. ESAT-6 subunit vaccination against Mycobacterium tuberculosis .  Infect Immun. 2000;  68 791-795
    CrossrefPubMedGoogle Scholar
  • 28 Horwitz M A, Harth G, Dillon B J, Maslesa-Galic S. Recombinant bacillus Calmette-Guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.  Proc Natl Acad Sci USA. 2000;  97 13853-13858
    CrossrefPubMedGoogle Scholar
  • 29 Olsen A W, van Pinxteren L AH, Okkels L M, Rasmussen P B, Andersen P. Protection of mice with a tuberculosis subunit vaccine based on a fusion protein of antigen 85B and ESAT-6.  Infect Immun. 2001;  69 2773-2778
    CrossrefPubMedGoogle Scholar
  • 30 Jungblut P R, Schaible U E, Mollenkopf H J et al.. Comparative proteome analysis of Mycobacterium tuberculosis and Mycobacterium bovis BCG strains: towards functional genomics of microbial pathogens.  Mol Microbiol. 1999;  33 1103-1117
    CrossrefPubMedGoogle Scholar
  • 31 Domenech P, Barry C E, Cole S T. Mycobacterium tuberculosis in the postgenomic age.  Curr Opin Microbiol. 2001;  4 28-34
    CrossrefPubMedGoogle Scholar
  • 32 Skeiky Y AW, Ovendale P J, Jen S et al.. T cell expression cloning of a Mycobacterium tuberculosis gene encoding a protective antigen associated with the early control infection.  J Immunol. 2000;  165 7140-7149
    PubMedGoogle Scholar
  • 33 Tascon R E, Colston M J, Ragno S, Stavropoulos E, Gregory D, Lowrie D B. Vaccination against tuberculosis by DNA injection.  Nat Med. 1996;  2 888-892
    PubMedGoogle Scholar
  • 34 Huygen K, Content J, Denis O et al.. Immunogenicity and protective efficacy of a tuberculosis DNA vaccine.  Nat Med. 1996;  2 893-898
    PubMedGoogle Scholar
  • 35 Behr M A, Wilson M A, Gill W P et al.. Comparative genomics of BCG vaccines by whole-genome DNA microarray.  Science. 1999;  284 1520-1523
    CrossrefPubMedGoogle Scholar
  • 36 Berthet F X, Lagranderie M, Gounon P et al.. Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene.  Science. 1998;  282 759-762
    CrossrefPubMedGoogle Scholar
  • 37 Yuan Y, Crane D D, Simpson R M et al.. The 16-kDa alpha-crystallin (Acr) protein of Mycobacterium tuberculosis is required for growth in macrophages.  Proc Natl Acad Sci USA. 1998;  95 9578-9583
    CrossrefPubMedGoogle Scholar
  • 38 McKinney J D, zu Bentrup K H, Munoz-Elias E J et al.. Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase.  Nature. 2000;  406 735-738
    CrossrefPubMedGoogle Scholar
  • 39 Cox J S, Chen B, McNeil M, Jacobs W R. Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice.  Nature. 1999;  402 79-83
    CrossrefPubMedGoogle Scholar
  • 40 Guleria I, Teitelbaum R, McAdam R A, Kalpana G, Jacobs W R, Bloom B R. Auxotrophic vaccines for tuberculosis.  Nat Med. 1996;  2 334-337
    PubMedGoogle Scholar
  • 41 Smith D A, Parish T, Stoker N G, Bancroft G J. Characterization of auxotrophic mutants of Mycobacterium tuberculosis and their potential as vaccine candidates.  Infect Immun. 2001;  69 1142-1150
    CrossrefPubMedGoogle Scholar
  • 42 Pym A S, Brodin P, Majlessi L et al.. Recombinant BCG exporting ESAT-6 confers enhanced protection against tuberculosis.  Nat Med. 2003;  9 533-539
    PubMedGoogle Scholar
  • 43 Hess J, Miko D, Catic A, Lehmensiek V, Russell D G, Kaufmann S HE. Mycobacterium bovis bacille Calmette-Guerin strains secreting listeriolysin of Listeria monocytogenes.  Proc Natl Acad Sci USA. 1998;  95 5299-5304
    CrossrefPubMedGoogle Scholar
  • 44 Murray P J, Aldovini A, Young R A. Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guerin strains that secrete cytokines.  Proc Natl Acad Sci USA. 1996;  93 934-939
    CrossrefPubMedGoogle Scholar
  • 45 Biet F, Kremer L, Wolowczuk I, Delacre M, Locht C. Mycobacterium bovis BCG producing interleukin-18 increases antigen-specific gamma interferon production in mice.  Infect Immun. 2002;  70 6549-6557
    CrossrefPubMedGoogle Scholar
  • 46 McShane H, Brookes R, Gilbert S C, Hill A VS. Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis.  Infect Immun. 2001;  69 681-686
    CrossrefPubMedGoogle Scholar
  • 47 Feng C G, Palendira U, Demangel C, Spratt J M, Malin A S, Britton W J. Priming by DNA immunization augments protective efficacy of Mycobacterium bovis bacille Calmette-Guerin against tuberculosis.  Infect Immun. 2001;  69 4174-4176
    CrossrefPubMedGoogle Scholar
  • 48 Brooks J V, Frank A A, Keen M A, Bellisle J T, Orme I M. Boosting vaccine for tuberculosis.  Infect Immun. 2001;  69 2714-2717
    CrossrefPubMedGoogle Scholar

Stefan H.E KaufmannPh.D. 

Max Planck Institute for Infection Biology, Department of Immunology

Schumannstrasse 21-22, D-10117 Berlin, Germany

Email: kaufmann@mpiib-berlin.mpg.de

      >